Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for EMPAGLIFLOZIN
- SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
- Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy XR Extended Release Film Coated Tablets
- Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
- Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
- Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
- Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
- Role of Finerenone in African American Veterans With Diabetic Kidney Disease
- Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
- A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
- Empagliflozin on Patients With Preserved Heart Failure
- A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY Kids)
- Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
- Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
- Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
- Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor
- A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Vascular Effects of SGLT2i in Non-diabetic CKD
- SGLT2i in Kidney Stones
- SGLT2i, Pioglitazone, and Ketone Production in T2D
- SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
- SGLT2i, Hepatic Glucose Production, and SNS
- To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.
- Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
- A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together
- Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
- Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
- A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food
- SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
- Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus
- New Triple Therapy in Newly Diagnosed Type 2 Diabetes
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
- Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
- A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
- Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
- The EMPA-FIT Study
- HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
- Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes
- Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
- Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, G
- Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: a Multicenter RCT
- Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany
- Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity
- Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
- Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
- Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors
- Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
- Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus
- EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source
- Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
- Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department
- SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
- Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
- Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
- Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age
- A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
- A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
- The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate
- Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
- Randomized Trial of SGLT2i in Heart Transplant Recipients
- Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
- Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
- Study Targeting Myocardial Perfusion and Symptom Relief in Women with SGLT2 Inhibitors (STRONG)
- To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
- Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin with Metformin
- Feasibility Trial for a Right Ventricular Failure Platform Trial
- Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
- A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
- Reducing Non-Alcoholic Steatohepatitis
- Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
- Empagliflozin Reversal of Arterial StiffnEss in Aging
- Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
- Efficacy of SGLT2 Inhibitors in Adults With Sepsis
- The Role of SGLT2i in Management of Moderate AS
- Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets
- Prevention of Progression of Prediabetes, Obesity and CV Risk
- Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
- Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
- Feasibility Trial of Sodium-GLucose CoTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
- Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
- Use of SGLT2i in noHCM With HFpEF
- Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
- SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus
- Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
- Empagliflozin for No-reflow Phenomenon in PCI for STEMI
- Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
- Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers
- Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
- A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
- Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD
- Efficacy of Sodium Glucose Transporter Inhibitor (SGLT2I) in Adult Patients with Congenital Heart Disease
- EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
- Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
- Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg
- Ketones, SGLT2, HFrEF
- Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia
- Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Co
- EMPagliflozin After Aortic Valve Replacement
- SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
- Impact of SGLT2 Inhibitors in Heart Transplant Recipients
- Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
- Polypill for Prevention of Cardiomyopathy
- SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
- Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity
- Empagliflozin to Prevent Post-Operative Atrial Fibrillation
- The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
- Assessment of Safety and Efficacy of SGLT2is Among LN Patients
- Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
- Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin
- Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus
- Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
- Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
- Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
- Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
- Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
- Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
- The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
- A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
- Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes
- Empagliflozin Treatment in Kidney Transplant Recipients
- Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)
- Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale
- The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes
- Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes
- The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
- Empagliflozin in Heart Failure Dialysis Patients
- Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
- SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis
- Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
- Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
- Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment
- Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study
- Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors
- Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
- Semaglutide and Vascular Regeneration
- Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
- Safety and Efficacy of Empagliflozin in Hemodialysis
- Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction
- Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
- Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
- The Fontan Dapagliflozin Pilot Study
- Empagliflozin in Patients With Cirrhosis and Ascites
- meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
- Empagliflozin in ESKD - A Feasibility Study
- Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
- Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
- Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
- Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
- Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
- Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
- Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Effect of Empagliflozin on Intestinal Microbiota in Patients With Heart Failure (LVEF>40%）
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
- Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
- Empagliflozin in Worsening Heart Failure
- Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy
- Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
- Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
- Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
- Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
- Empagliflozin in Pulmonary Arterial Hypertension
- Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
- Empagliflozin as a Novel Therapy in Refractory Ascites
- Use of Empagliflozin to Treat Prediabetes
- Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus
- Impact of SGLT2 on Glucosuria in HNF1A-MODY
- Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
- Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
- Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
- Canagliflozin and Myocardial Micro-perfusion
- The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
- Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
- Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
- DAPAgliflozin for Renal Protection in Heart Transplant Recipients
- Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial
- Empagliflozin in Acute Heart Failure
- Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
- Empagliflozin in Patients With Glomerulonephritis
- A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to th
- HF Patients With LAVDs Being Treated With SGLT2i
- Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
- A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
- Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment
- SGLT2 Inhibitors in ATTR
- Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
- Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions
- SGLT2 Inhibition: Uric Acid Excretion Study
- Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome
- A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
- Empagliflozin in Hypertrophic Cardiomyopathy
- SGLT2 Inhibition in Hemodialysis
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
- Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
- Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B
- Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
- Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction
- SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
- Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)
- Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial
- Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes
- The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
- A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together
- SNIFF - Combo INI+EMPA Trial
- Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
- Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis
- Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass
- SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
- The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction
- The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
- Anti-diabetic Drugs and Fatty Liver Management
- Effect of UGT Genetic Variation on Pharmacokinetics of Empagliflozine
- Empagliflozin for the Treatment of Postprandial Hypoglycemia
- Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
- EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
- Empagliflozin in Diuretic Refractory Ascites
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)
- Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
- Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
- Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia
- Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation
- Empagliflozin in Adolescent Diabetes
- Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers
- Follow-up of NAFLD Patients With MRI-PDFF
- SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
- Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
- GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
- Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)
- Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
- Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus
- Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose
- Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
- Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
- Combined Active Treatment in Type 2 Diabetes With NASH
- Polypill Strategy for Heart Failure With Reduced Ejection Fraction
- Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
- Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
- Empagliflozin and Atrial Fibrillation Treatment
- Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)
- Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
- A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
- A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
- EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
- Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions
- Empagliflozin and Cardiac Remodelling in People Without Diabetes
- Low Dose Empagliflozin in Adults With Type 1 Diabetes on Closed Loop Insulin System
- Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
- Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin
- Antidiabetic Triple Therapy Effects on Surrogate Tests After Stroke
- Randomised Evaluation of COVID-19 Therapy
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
- Pharmacological Reduction of Right Ventricular Enlargement
- The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.
- Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs
- REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations
- Renohemodynamic Effects of Combined empagliflOzin and LosARtan
- A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
- The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes
- A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )
- The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
- Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD
- Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
- Short Term Effect of Empagliflozin in Hypertension
- Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus
- Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)
- A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
- SGLT2 Inhibitors in Glomerular Hyperfiltration
- Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina
- Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency
- Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes
- Effect of Empagliflozin on Ventricular Repolarization.
- Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria
- Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
- A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
- Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
- Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting
- Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy
- Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
- EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
- Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
- Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans
- The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin
- Dapagliflozin Plus Pioglitazone in T1DM
- Effect of Empagliflozin on Body Composition and Ketones
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
- Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
- Drug Interaction Study Between Dorzagliatin and Empagliflozin
- Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
- Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults
- Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus
- Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
- Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver
- This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
- EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
- Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
- Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
- Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol
- Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors
- EMPA Acute Heart Failure
- Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin
- Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
- Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
- Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
- Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension
- This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
- This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
- Empagliflozin Effect on Glucose Toxicity
- Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
- Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
- ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
- Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
- A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin
- Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
- This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
- Empagliflozin and Sympathetic Nerve Traffic
- Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes
- SGLT2 Inhibition in Combination With Diuretics in Heart Failure
- Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes
- Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
- Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
- Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
- Empaglifozin in Early Diabetic Kidney Disease
- Empagliflozin in Renal Transplant Recipients
- A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
- SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk
- Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
- Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
- Impact of Empaglifozine on Cardiac Ectopic Fat
- Empagliflozin in Post-Transplantation Diabetes Mellitus
- Empagliflozin and Renal Oxygenation in Healthy Volunteers
- Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
- EMPRA (EMPagliflozin and RAs in Kidney Disease)
- Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
- SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
- Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
- Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
- Empagliflozin vs Metformin in PCOS
- Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes
- Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
- Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
- The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
- Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
- Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
- Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
- Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
- The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
- Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
- Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin
- JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
- Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
- Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets
- Empa/Lina FDC Food Effect Study (Japan)
- SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.
- The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
- Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers
- The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
- Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects
- Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
- Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
- SGLT2 Inhibition and Left Ventricular Mass
- Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
- Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
- Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
- Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
- A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
- Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
- Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
- Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
- Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
- Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
- Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function
- Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
- Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
- Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
- Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
- Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
- 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
- Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
- Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets
- Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers
- Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
- Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets
- Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
- Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets
- Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
- Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
- Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
- Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
- Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
- Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
- Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
- Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
- Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets
- A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
- Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid
- Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
- Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.
- Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
- Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
- 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
- Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
- Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus
- Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin
- Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers
- Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
- Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
- DDI Between BI Empagliflozin (10773) and Verapamil
- Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
- A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
- Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers
- Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
- Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
- Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
- Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
- Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
- Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
- Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
- Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
- Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
- BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
- Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers
- Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
- Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
- 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
- Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
Clinical trials list
click for details